KLRK1 and neoplasm: Tumor-derived EVs also express the surface ligands of NKG2D, such as ULBP-2 and MICA/MICB, acting as negative regulators of NKG2D on NK cells in a dose-dependent manner and impairing cytotoxicity against tumor cells [107].